BFH772 (VEGFR2 Inhibitor): Technical Use and Protocol Guidance

What This Product Solves

BFH772 (SKU B6199) is a small-molecule VEGFR2 kinase inhibitor designed for selective inhibition of the VEGFR2 signaling pathway in angiogenesis research. With a low nanomolar IC₅₀ of 3 nM for VEGFR2 and a marked selectivity profile—demonstrating much lower activity against related kinases—it allows researchers to study VEGFR2-driven angiogenic processes with minimal off-target interference. This selectivity is particularly valuable in tumor model workflows where dissecting VEGFR2 function is critical for understanding and modulating tumor vascularization. BFH772 is not suitable for applications requiring water-soluble inhibitors or those targeting a broad range of kinases.

For additional parameter guidance and protocol tips, see BFH772: Technical Use and Protocol Guidance (covers solubility and specificity considerations), and BFH772: Technical Guide and Workflow Parameters (focuses on workflow suitability and storage).

Protocol Parameters

• Assay: VEGFR2 kinase inhibition
  Value: IC₅₀ = 3 nM
  Applicability: Use for experiments requiring high-affinity, selective VEGFR2 pathway inhibition.
  Rationale: Enables precise dissection of VEGFR2-mediated angiogenesis with minimized off-target kinase effects.
  Source: product information
• Assay: Compound solubility in DMSO
  Value: ≥53.4 mg/mL
  Applicability: Suitable for preparing high-concentration stock solutions in DMSO for in vitro and in vivo dosing.
  Rationale: High DMSO solubility supports flexible dosing and serial dilution while maintaining compound stability.
  Source: product information
• Assay: Storage temperature (dry powder)
  Value: -20°C
  Applicability: Essential for long-term preservation of compound integrity.
  Rationale: Maintains chemical stability and prevents degradation; avoid repeated freeze-thaw cycles.
  Source: product information
• Assay: Stock solution storage (in DMSO or ethanol)
  Value: Short-term only; long-term storage not recommended
  Applicability: Prepare fresh working solutions before each experiment.
  Rationale: Prolonged storage in solution increases risk of hydrolysis and potency loss.
  Source: product information
• Assay: Water solubility
  Value: Insoluble
  Applicability: Not compatible with aqueous-only workflows.
  Rationale: Requires use of organic solvents (DMSO, ethanol) for all working solutions.
  Source: product information

Workflow Setup and QC Checklist

• Solvent selection: Use DMSO or ethanol to dissolve BFH772 at the required concentration. Confirm complete dissolution before diluting into assay buffer. Do not attempt to dissolve directly in water.
• Stock preparation: Prepare high-concentration stock solutions (e.g., 10-50 mM) in DMSO. Filter sterilize if required and aliquot to minimize freeze-thaw cycles.
• Working solution: Dilute stock solutions freshly into the final assay medium immediately before use, ensuring the final organic solvent concentration is compatible with your biological system.
• Storage and handling: Store BFH772 powder at -20°C in a desiccated environment. Avoid repeated exposure to moisture or light. Discard any unused stock solutions after each experimental session.
• Quality control: Reference the certificate of analysis and verify compound purity (>96%) before use. Confirm batch identity using the provided CAS number (890128-81-1) and molecular weight (439.39).

Common Failure Modes and Fixes

• Poor dissolution: If undissolved material remains after vortexing, gently heat to 37°C or sonicate briefly. Do not use water as a solvent.
• Loss of activity: If experimental inhibition is lower than expected, check for compound degradation due to improper storage or repeated freeze-thaw cycles. Always prepare fresh solutions.
• Precipitation in assay: If precipitation occurs on dilution into aqueous buffer, increase the initial DMSO concentration within the acceptable limit for your assay system, or pre-mix with a small volume of serum or carrier protein.
• Off-target effects: Although BFH772 is selective, test for non-specific effects by including appropriate vehicle and off-target controls in your workflow.

Scope and Limitations

• Scope: BFH772 is intended for research applications where selective inhibition of the VEGFR2 signaling pathway is required, such as studies on angiogenesis or tumor vascularization in cell-based or animal models.
• Limitations: Not suitable for workflows that demand aqueous solubility or broad-spectrum kinase inhibition. Solubility constraints require the use of organic solvents, which must be compatible with the chosen biological system. Long-term stock solution storage is not advised due to risk of compound degradation. The product’s selectivity profile limits its use to VEGFR2-focused research questions.
• Not for clinical or diagnostic use: Intended for in vitro and preclinical research only.

Conclusion

BFH772 (VEGFR2 inhibitor, APExBIO) is a technically validated, highly selective tool for dissecting VEGFR2-driven angiogenic mechanisms in tumor and vascular biology research. Protocol adherence—especially regarding compound solubility, storage, and solution freshness—is critical for reproducible results. By following the above workflow guidelines and recognizing scope limitations, researchers can maximize the utility of this anti-angiogenic agent in targeted VEGFR2 pathway studies.